专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010117323A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE 审中-公开
标题翻译：生产热能和二氧化碳的方法和装置
公开(公告)号：WO2010117323A1
公开(公告)日：2010-10-14
申请号：PCT/SE2010/050375
申请日：2010-04-06
申请人： ASTRAZENECA AB , BOSTRÖM, Jonas , CHENG, Leifeng , FEX, Tomas , KARLE, Michael , PETTERSEN, Daniel , SCHELL, Peter
发明人： BOSTRÖM, Jonas , CHENG, Leifeng , FEX, Tomas , KARLE, Michael , PETTERSEN, Daniel , SCHELL, Peter
IPC分类号： C07D413/04 , A61K31/4523 , A61P7/04
CPC分类号： C07D413/04
摘要： Formula I or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprising O or N and optionally substituted with a C1-10 alkyl or aryl, hetero aryl optionally substituted with R3.
摘要翻译：式I或其药学上合适的盐，其中R 1和R 2独立地是氢，氘，芳基，杂芳基，任选被一个或多个取代基独立地被R 3取代的C 1 -C 8烷基，R 3是芳基，杂芳基，氟，含有一个或多个氟的C 1 -C 6烷基，含有一个或多个氘的C 1 -C 6烷基，含羟基的C 1 -C 6烷基，任选被一个或多个卤素取代的芳基和杂芳基，氟化烷氧基，氟化烷基，磺酰基，一个或多个氘，C 1-6烷基，C 1-6烷氧基，腈或R 3是任选被一个或多个下列基团取代的C 1-6烷基：COOR 4， OCOR4，CONR5R6，NR5COR6，OR4; 其中，R4为任选被一个或多个氟，氘，烷氧基，芳基羧酸酯，羧酸烷基酯取代的C 1-10烷基; R 5和R 6独立地选自氢，烷基或它们可以一起形成4-8元碳环; 或R 1和R 2形成任选地包含O或N并任选被C 1-10烷基或芳基取代的3-10元碳环，任选被R 3取代的杂芳基。

2. 发明申请

WO2006073361A1 NOVEL PYRIDINE COMPOUNDS 审中-公开
标题翻译：新型吡啶化合物
公开(公告)号：WO2006073361A1
公开(公告)日：2006-07-13
申请号：PCT/SE2006/000010
申请日：2006-01-04
申请人： ASTRAZENECA AB , BACH, Peter , BOSTRÖM, Jonas , BRICKMANN, Kay , CHENG, Leifeng , GIORDANETTO, Fabrizio , GRONEBERG, Robert D. , HARVEY, Darren, Martin , O'SULLIVAN, Michael, F. , ZETTERBERG, Fredrik , ÖSTERLUND, Krister
发明人： BACH, Peter , BOSTRÖM, Jonas , BRICKMANN, Kay , CHENG, Leifeng , GIORDANETTO, Fabrizio , GRONEBERG, Robert D. , HARVEY, Darren, Martin , O'SULLIVAN, Michael, F. , ZETTERBERG, Fredrik , ÖSTERLUND, Krister
IPC分类号： C07D401/04 , A61K31/4427 , A61P7/02 , C07D213/78 , C07D401/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14
CPC分类号： C07D413/14 , C07D401/04 , C07D401/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要： The present invention relates to certain novel pyridin compounds of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
摘要翻译：本发明涉及式（I）的某些新颖的吡啶化合物，用于制备这些化合物的方法，以其作为P2Y12抑制剂和抗血栓形成剂等的用途及其制备方法，它们作为心血管疾病中的药物使用作为含有它们的药物组合物。

3. 发明申请

WO2009041904A1 QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR 审中-公开
标题翻译：具有抗GABAB受体活性的喹啉化合物
公开(公告)号：WO2009041904A1
公开(公告)日：2009-04-02
申请号：PCT/SE2008/051077
申请日：2008-09-26
申请人： ASTRAZENECA AB , CHENG, Leifeng , KARLE, Michael
发明人： CHENG, Leifeng , KARLE, Michael
IPC分类号： C07D215/38 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61P1/04 , A61P1/10 , A61P1/12 , C07D215/18 , C07D401/06 , C07D401/12
CPC分类号： C07D215/18 , C07D215/38 , C07D215/54 , C07D401/06 , C07D401/12
摘要： 62 Abstract The present invention relates to novel compounds of the general formula (I) N R1 R4 R5 X 5 (I) wherein R1, R4, R5 and X are as defined, having a positive allosteric GABA Breceptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA Bagonist, for the inhibition of transient lower esophageal sphincter relaxations, 10 for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
摘要翻译： 62摘要本发明涉及通式（I）的新化合物，其中R 1，R 4，R 5和X如上所定义，具有正的变构GABA受体（GBR）调节剂效应，方法用于制备所述化合物及其用途，任选地与GABA Bagonist组合用于抑制短暂食管下括约肌松弛，10用于治疗胃食管反流疾病，以及治疗功能性胃肠道疾病和易激惹肠综合征（IBS）。

4. 发明申请

WO2009041905A1 PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS 审中-公开
标题翻译：在GABA受体上具有活性的吡啶化合物
公开(公告)号：WO2009041905A1
公开(公告)日：2009-04-02
申请号：PCT/SE2008/051078
申请日：2008-09-26
申请人： ASTRAZENECA AB , CHENG, Leifeng , JONFORSEN, Maria , SCHELL, Peter
发明人： CHENG, Leifeng , JONFORSEN, Maria , SCHELL, Peter
IPC分类号： C07D475/02 , A61K31/519 , A61P1/04 , A61P1/10 , A61P1/12 , C07D475/12
CPC分类号： C07D475/02
摘要： 62 Abstract The present invention relates to novel compounds of the general formula (I) NN N X O O R1 R2 R4 R3 5 (I) wherein R1, R2, R3 and R4 are as defined, having a positive allosteric GABA Breceptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA Bagonist, for the inhibition of transient lower esophageal sphincter relaxations, 10 for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
摘要翻译： 62摘要本发明涉及通式（I）的新化合物，其中R 1，R 2，R 3和R 4如所定义，具有正的变构GABA受体（GBR）调节剂作用，用于制备所述化合物的方法及其用途，任选地与GABA Bagonist组合用于抑制短暂的食管下括约肌松弛，10用于治疗胃食管反流疾病，以及治疗功能性胃肠道疾病，以及肠易激综合征（IBS）。

5. 发明申请

WO2007010217A1 PYRAZOLE DERIVATIVES AS CBl MODULATORS 审中-公开
标题翻译：作为CBI调节剂的吡唑衍生物
公开(公告)号：WO2007010217A1
公开(公告)日：2007-01-25
申请号：PCT/GB2006/002631
申请日：2006-07-17
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng , JONFORSEN, Maria , SCHELL, Peter
发明人： CHENG, Leifeng , JONFORSEN, Maria , SCHELL, Peter
IPC分类号： C07D401/12 , C07D231/14 , A61P3/04 , A61P25/28 , A61P25/18
CPC分类号： C07D231/14 , C07D401/12
摘要： The present invention relates to compounds of formula (I) wherein R 1 represents a group R 5 O- in which R 5 represents a C 3-7 alkyl group substituted by one or more fluoro or R 5 represents a C 3-7 alkylsulphonyl group which is optionally substituted by one or more fluoro; R 2 represents a C 1-4 alkyl group, hydroxy, fluoro, chloro or cyano wherein each R 2 is independently selected when n is >1; R 3 represents a) cyclohexyl optionally substituted by one or more of the following: hydroxy, fluoro, amino, mono or diC 1-3 alkylamino, carboxy or a C 1-4 alkoxycarbonyl group b) piperidino substituted by one or more hydroxy c) unsubstituted piperidino but only when one of the following applies: R 4 represents cyano or R 1 represents 3-fluoropropylsulphonyloxy or R 1 represents 3,3,3-trifluoropropoxy or R 1 represents 3-fluoropropoxy or R 2 is methyl d) phenyl substituted by one or more of the following: hydroxy, halo or a C 1-4 alkyl group e) pyridyl substituted by a C 1-4 alkyl group or f) a C 4-9 alkyl group; R 4 represents cyano or methyl; and n is 1, 2 or 3 and pharmaceutically acceptable salts thereof and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式（I）的化合物，其中R 1表示基团R 5 O，其中R 5表示C 1〜被一个或多个氟或R 5取代的C 3-7烷基表示任选被一个或多个氟取代的C 3-7烷基磺酰基氟; R 2表示C 1-4烷基，羟基，氟，氯或氰基，其中当n是>时独立地选择每个R 2， 1; R 3表示a）任选被以下一个或多个取代的环己基：羟基，氟，氨基，单或二-C 1-3烷基氨基，羧基或C _{代表3-氟丙基磺酰氧基或R 1代表3,3,3-三氟丙氧基或R 1代表3-氟丙氧基或R 2是甲基d）被一个或多个下列基团取代的苯基：羟基，卤素或C 1-4烷基; e）被C 1-4烷基取代的吡啶基或f）C 4-9烷基; R 4表示氰基或甲基; 和n为1,2或3及其药学上可接受的盐及其制备方法，它们在治疗肥胖症，精神病学和神经障碍中的应用，以及其治疗用途的方法和含有它们的药物组合物。}

6. 发明申请

WO2012047156A1 ISOXAZOL-3(2H)-ONE ANALOGS AS PLASMINOGEN INHIBITORS AND THEIR USE IN THE TREATMENT OF FIBRINOLYSIS RELATED DISEASES 审中-公开
标题翻译： ISOXAZOL-3（2H）-ONE ANALOGS AS PLASMINOGEN INHIBITORS AND THEISE IN US TREATMENT OF FIBRINOLYSIS DISAASES
公开(公告)号：WO2012047156A1
公开(公告)日：2012-04-12
申请号：PCT/SE2011/051172
申请日：2011-10-03
申请人： ASTRAZENECA AB , CHENG, Leifeng , SCHELL, Peter
发明人： CHENG, Leifeng , SCHELL, Peter
IPC分类号： C07D413/04 , A61K31/4523 , A61K31/4985 , A61P7/04 , C07D413/14 , C07D487/04
CPC分类号： C07D413/14 , C07D487/04
摘要： A compound of formula (I): wherein R1 is hydrogen; R2 is C 1 -C 10 alkyl, which C 1 -C 10 alkyl comprises 0, 1, 2, 3 or 4 heteroatoms, selected from O and N, or 0, 1 or 2 acid, ester or amide functionalities, and said C 1 -C 10 alkyl is substituted by 0, 1, 2, 3 or 4 CH 3 , halogen or CF 3 , or -XR20, wherein X is a bond or _-CH 2 -, and R20 is a 4 to 10 membered, monocyclic or bicyclic heterocyclic aromatic or non-aromatic ring containing 1, 2, 3 or 4 heteroatoms selected from O and N, and R20 is substituted by 0, 1, 2, 3 or 4 CH3, halogen or CF3, pharmaceutical compositions, medical uses and treatment or prophylaxis of a disease or condition in which modulation of fibrinolysisis is beneficial.
摘要翻译：式（I）的化合物：其中R 1是氢; R 2是C 1 -C 10烷基，其中C 1 -C 10烷基包括0,1,2,3或4个选自O和N，或0,1或2个酸，酯或酰胺官能团的杂原子，并且所述C 1 -C 10烷基是被0,1,2,3或4个CH 3，卤素或CF 3或-XR 2 O取代，其中X是一个或多个-CH 2 - ，R 20是4至10元的单环或双环杂环芳族或非芳族含有1,2,3或4个选自O和N的杂原子的环，R 20被0,1,2,3或4个CH 3，卤素或CF 3取代，药物组合物，医学用途和治疗或预防疾病或病症其中纤维蛋白溶解的调节是有益的。

7. 发明申请

WO2008130314A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT 审中-公开
标题翻译：具有阳性GABAB受体调节剂效应的XANTHINE化合物
公开(公告)号：WO2008130314A1
公开(公告)日：2008-10-30
申请号：PCT/SE2008/050435
申请日：2008-04-17
申请人： ASTRAZENECA AB , CHENG, Leifeng , HOLMQVIST, Sara , RAUBACHER, Florian , SCHELL, Peter
发明人： CHENG, Leifeng , HOLMQVIST, Sara , RAUBACHER, Florian , SCHELL, Peter
IPC分类号： C07D487/04 , A61K31/522 , A61P1/04
CPC分类号： C07D473/04 , C07D473/06 , C07F7/1856
摘要： The present invention relates to novel xanthine compounds of the general formula (I) wherein R 1 , R 2 , R 3 and R 4 are as defined, having a positive allosteric GABA Breceptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA Bagonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
摘要翻译：本发明涉及通式（I）的新颖的黄嘌呤化合物，其中R 1，R 2，R 3和R 2， 4定义为具有正的变构GABA受体（GBR）调节剂效应，用于制备所述化合物的方法及其用途，任选地与GABA Bagonist组合用于抑制短暂的食管下括约肌松弛，用于治疗胃食管反流疾病，以及治疗功能性胃肠道疾病和肠易激综合征（IBS）。

8. 发明申请

WO2008130313A1 IMIDAZOLE DERIVATIVES AS MODULATORS OF THE GABA RECEPTOR FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 审中-公开
标题翻译：作为治疗胃肠疾病的GABA受体的调节剂的咪唑衍生物
公开(公告)号：WO2008130313A1
公开(公告)日：2008-10-30
申请号：PCT/SE2008/050434
申请日：2008-04-17
申请人： ASTRAZENECA AB , BAUER, Udo , BRAILSFORD, Wayne , CHENG, Leifeng , JONFORSEN, Maria , RAUBACHER, Florian , SCHELL, Peter , SVENSSON, Tor
发明人： BAUER, Udo , BRAILSFORD, Wayne , CHENG, Leifeng , JONFORSEN, Maria , RAUBACHER, Florian , SCHELL, Peter , SVENSSON, Tor
IPC分类号： C07D233/88 , A61K31/4164 , A61K31/4178 , A61P1/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12
CPC分类号： C07D233/90 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12
摘要： The present invention relates to novel imidazole compounds having a positive allosteric GABA B receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA B agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
摘要翻译：本发明涉及具有正变构GABA B受体（GBR）调节剂效应的新型咪唑化合物，其制备方法及其用途，任选地与GABA B 用于抑制短暂食管下括约肌松弛，用于治疗胃食管反流疾病，以及治疗功能性胃肠道疾病和肠易激综合征（IBS）。

9. 发明申请

WO2006067443A1 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药剂
公开(公告)号：WO2006067443A1
公开(公告)日：2006-06-29
申请号：PCT/GB2005/004977
申请日：2005-12-21
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng
发明人： CHENG, Leifeng
IPC分类号： C07D231/22 , C07D231/24 , A61K31/415 , A61P25/00
CPC分类号： C07D231/14 , C07D401/12
摘要： The present invention relates to 1,5-diphenylpyrazole compounds of formula I (A chemical formula should be inserted here - please see paper copy enclosed herewith) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式I的1,5-二苯基吡唑化合物（这里应插入一种化学式，请参见随附的纸质复制品）及其制备方法，用于治疗肥胖症，精神病和神经障碍，其治疗用途的方法和含有它们的药物组合物。

10. 发明申请

WO2008120000A1 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药剂
公开(公告)号：WO2008120000A1
公开(公告)日：2008-10-09
申请号：PCT/GB2008/001165
申请日：2008-04-02
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng , HELGESSON, Sara, Annelie , JUDKINS, Robert, Andrew , LINDHAGEN, Marika, Jenny, Susanna , PONTÉN, John, Fritiof
发明人： CHENG, Leifeng , HELGESSON, Sara, Annelie , JUDKINS, Robert, Andrew , LINDHAGEN, Marika, Jenny, Susanna , PONTÉN, John, Fritiof
IPC分类号： C07D471/04 , A61K31/437 , A61P3/04
CPC分类号： C07D471/04
摘要： Certain 4, 5, 6, 7 -tetrahydropyrrolo[3,2-c]pyridin-4-one and 4, 5 -dihydropyrrolo[3,2- c ]pyridin-4-one compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, methods for their therapeutic use and pharmaceutical compositions containing them are described.
摘要翻译：一些式（I）的4,5,6,7-四氢吡咯并[3,2-c]吡啶-4-酮和4,5,5-二氢吡咯并[3,2-c]吡啶-4-酮化合物，制备描述了这些化合物，它们在治疗肥胖症，精神病学和神经病学障碍中的用途，其治疗用途的方法和含有它们的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式